How Much Would A Kidney Cost?

In the United States, it is illegal to buy or sell a human kidney. So the honest answer to what a kidney would cost is this: there is no legal market price. What exists instead is a set of real numbers that describe what a kidney transplant costs, what dialysis costs, and what people in black markets abroad have reportedly paid. Those numbers are very different from each other, and mixing them up is where most online answers go wrong.

Why You Cannot Legally Buy a Kidney in the US

The National Organ Transplant Act of 1984 made it a federal crime to give or receive “valuable consideration” for a human organ. That means cash, cars, housing, tuition — anything of value. Violating the law can bring prison time and fines.

The rationale is not that organs have no value. It is that a legal market could exploit poor and desperate people. Most countries with transplant programs have similar bans. Iran is the notable exception, running a regulated system that pays donors. It is the only country widely described as having a legal paid kidney donation program.

What the law does allow is reimbursement. A living donor can typically have travel, lodging, lost wages, and medical costs covered. That is compensation for expenses, not payment for the organ itself. The distinction matters legally and ethically, and it is the line that separates a lawful donation from a felony.

What a Kidney Transplant Actually Costs

A kidney transplant in the US is expensive — but the price depends entirely on who is paying and how you count. Billing charges, negotiated insurance rates, and actual amounts paid are three different numbers, and they can differ by a factor of several.

Published hospital charge data and transplant cost analyses generally place the first-year cost of a kidney transplant in the range of roughly $300,000 to $450,000 before insurance adjustments. That figure typically includes the organ procurement fee, surgery, hospital stay, and the first year of immunosuppressant drugs and follow-up care. Ongoing costs after the first year are much lower, mostly medications and monitoring, but they continue for the life of the transplant.

For most patients, Medicare or private insurance covers the bulk of this. Medicare covers immunosuppressant drugs for transplant patients, though coverage rules and time limits have changed over the years, so patients should verify current terms directly with their plan.

One detail that surprises people: the “organ acquisition fee” is a real line item. It covers the cost of evaluating the donor, recovering the organ, and preserving and transporting it. It is not a payment to the donor. It is a payment to the hospital and organ procurement organization for the work involved.

What Dialysis Costs by Comparison

Dialysis is the alternative when no transplant is available, and it is not cheaper over time. It is more expensive.

Medicare spending on dialysis for patients with end-stage renal disease runs into the tens of billions of dollars annually in the US. Per-patient, hemodialysis typically costs somewhere in the range of $90,000 or more per year depending on setting and payer. A transplant costs more up front but generally costs less per year afterward, which is one reason transplant is considered the preferred treatment for most eligible patients.

That comparison is also the reason economists and bioethicists keep debating whether paying donors would save the system money. The argument is straightforward: if paid donation increased the supply, fewer people would stay on dialysis. The counterargument is that a legal market could pressure poor people into selling an organ they may later need, and that the long-term health risks to donors are not fully understood.

What People Reportedly Pay in Black Markets

There is no reliable price for an illegal kidney. Reports from journalists and researchers who have documented underground organ markets in South Asia, the Middle East, and parts of Latin America describe payments to donors in the low thousands of dollars, while the recipient or a broker may pay far more.

These numbers should be treated with real caution. They come from investigative reporting, not from audited data. They vary widely by country, year, and how the deal was structured. Anyone quoting a single global figure is almost certainly overstating what is known.

What is better documented is the harm. Studies of paid donors in countries like India and Pakistan have found that many did not receive the follow-up care they were promised, did not see lasting financial benefit, and in some cases ended up worse off economically than before. The World Health Organization has urged countries to prevent organ trafficking and transplant tourism, and most have laws against it.

How the Kidney Allocation System Works Instead

In the US, kidneys from deceased donors are distributed through a national system run by the Organ Procurement and Transplantation Network, which is overseen by the federal government and operated under contract by the United Network for Organ Sharing.

The system has changed over time. A major revision in 2014 shifted priority toward candidates based on a combination of factors, including how long they have been waiting and how well a donor kidney is expected to match. Patients with high levels of antibodies against donor tissue — called sensitized patients — also receive priority under certain rules, because finding a compatible kidney for them is harder.

Living donation is different. A patient can receive a kidney from a family member, friend, or an anonymous altruistic donor. Paired exchange programs allow incompatible pairs to swap donors so both patients get a match. These programs have expanded access without any payment changing hands.

The waiting list is long. Thousands of people die each year while waiting for a kidney, and the gap between supply and demand is the core reason the payment debate keeps resurfacing.

Why the Payment Debate Has Not Been Settled

The case for paying donors rests on a simple observation: the shortage is severe, and a legal, regulated market might reduce it. Some economists have argued that a regulated system with safeguards could be designed to protect donors rather than exploit them.

The case against is also strong. A 2014 review and several subsequent analyses have raised concerns that financial incentives could disproportionately attract low-income donors, that the long-term health risks of living with one kidney — though generally modest — are not zero, and that a market could undermine public trust in donation. There is also the practical problem that most proposals for a legal market have not been tested at scale, so their real-world effects are unknown.

No country other than Iran has adopted a legal paid system, which means the evidence on how such a system would work in practice is thin. That is not a moral argument either way. It is simply what the data show.

What Living With One Kidney Means

Most people who donate a kidney live normal, healthy lives. Research on long-term donor outcomes generally shows a small increase in risk of high blood pressure and, in some studies, a modestly higher risk of end-stage kidney disease compared with the general population — though the absolute risk remains low.

Donors are screened carefully before donation, which partly explains why donor outcomes tend to look better than average. People with existing kidney problems, uncontrolled high blood pressure, diabetes, or certain other conditions are not accepted as donors.

The screening process is one reason the ethics of paid donation are complicated. A regulated medical system screens donors. An underground market often does not.

What This Means If You or Someone You Know Needs a Kidney

The practical path is not to look for a price. It is to understand the options that exist legally.

• Get on the transplant waiting list as early as your care team recommends. Time on the list affects priority.
• Ask about living donation. A living donor kidney often lasts longer than a deceased donor kidney and can be scheduled before dialysis becomes necessary.
• Ask about paired exchange if a willing donor is not a match.
• Check what your insurance or Medicare covers for transplant and for immunosuppressant drugs after.
• Be cautious of anyone offering to arrange a paid transplant abroad. That is transplant tourism, and it carries legal, medical, and follow-up risks.

Financial assistance programs exist for transplant patients, including help with travel, lodging, and medication costs. Transplant centers usually have social workers who can point patients toward them.